QNCX Quince Therapeutics, Inc.
26.72USD-0.34%Mkt Cap: 27.18M $P/E: —1d ago
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap27.18M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-83.98M USD
Revenue/Share—
Last Price26.72 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.72
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.77
EPS (TTM)—
EPS (Forward)—
52W Range
15.101% of range910.00
52W High910.00 USD
52W Low15.10 USD
Profitability
Gross Margin—
Oper. Margin—
EBITDA Margin—
Profit Margin—
ROE235.14%
ROA-89.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.42M USD
CapEx (TTM)352.00K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.52
Current Ratio—
Quick Ratio—
Book Value/Sh-34.73 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.02M
Float—
Insiders—
Institutions—
Technical
SMA 5029.76 (-10.2%)
SMA 200112.64 (-76.3%)
Beta—
S&P 52W Chg—
Avg Vol (30d)22.33K
Avg Vol (10d)—
Technical Indicators
RSI (14)40.3
MACD-0.2610
MACD Signal0.3134
MACD Hist.-0.5743
BB Upper32.32 USD
BB Middle29.59 USD
BB Lower26.86 USD
BB Width18.47%
ATR (14)2.120 USD
Vol Ratio (20d)0.53x